• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of the effect for proliferation & therapeutic sensitivity according to specific binding protein for each hypoxia-inducible factor(HIF) 1α & 2α

Research Project

Project/Area Number 21592054
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionYokohama City University

Principal Investigator

KONDO Keiichi  横浜市立大学, 市民総合医療センター, 准教授 (80363836)

Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
KeywordsHIF / 結合蛋白 / 低酸素環境 / 腎細胞癌 / 治療感受性
Research Abstract

(Introduction) Renal cell carcinoma specimens show variable staining pattern of hypoxia-inducible factor(HIF) 1α & 2α. HIF1α & 2αhave high homology, but different function. So far, it has not been clear what kind of function these proteins have specifically. To clarify this point, we search specific binding proteins for each HIFα.
(Materials & Methods) We extract proteins from renal cell carcinoma cell line ACHN & SN12C, which show normal von Hippel-Lindau(VHL) protein function and express both HIFαs under hypoxic condition, and immunoprecipitated them to find specific binding proteins with HIFα specific antibodies. Co-immunoprecipetated proteins were dissolved by SDS-PAGE, and expression level compared by silver staining.
(Results & future plans) We could detect several candidate bands, which shows stronger expression compared with samples co-precipitated by control antibody. Next we tried to dissolve them by 2D-electrophoresis and picked up candidate spots to do mass-spectrometry analysis. But amount of these proteins were so little and we could not get reliable results, so far. It is unable to amplify these proteins in cancer cells, because we had not yet identified. Now we try to enhance affinity between HIFαs & these proteins. We change culture conditions such as oxygen and/or glucose concentrations to optimize each HIFα expression, respectively and check the affinity under such conditions.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report
  • Research Products

    (4 results)

All 2011 2010

All Presentation (4 results)

  • [Presentation] mTOR阻害薬は低酸素及び低栄養状態の細胞にも増殖抑制効果を示す2011

    • Author(s)
      近藤慶一
    • Organizer
      第70回日本癌学会学術総会
    • Place of Presentation
      名古屋
    • Year and Date
      2011-10-03
    • Related Report
      2011 Annual Research Report
  • [Presentation] mTOR阻害薬は低酸素及び低栄養状態の細胞にも増殖抑制効果を示す2011

    • Author(s)
      近藤慶一
    • Organizer
      第70回日本癌学会総会
    • Place of Presentation
      名古屋
    • Related Report
      2011 Final Research Report
  • [Presentation] HIF pathway and mTOR pathway ; How they influenced each other in RCC growth & progression?2010

    • Author(s)
      近藤慶一
    • Organizer
      第69回日本癌学会学術総会
    • Place of Presentation
      大阪
    • Year and Date
      2010-09-24
    • Related Report
      2010 Annual Research Report
  • [Presentation] HIF1α及びHIF2αによる腎細胞癌増殖制御機構におけるmTOR経路の関与2010

    • Author(s)
      近藤慶一
    • Organizer
      第69回日本癌学会総会
    • Place of Presentation
      大阪
    • Related Report
      2011 Final Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi